U.S. Markets close in 4 hrs 54 mins
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.28
    -0.43 (-0.94%)
     
  • Gold

    1,809.60
    -1.60 (-0.09%)
     
  • Silver

    23.25
    -0.20 (-0.84%)
     
  • EUR/USD

    1.1930
    +0.0017 (+0.1432%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.34
    -0.30 (-1.39%)
     
  • GBP/USD

    1.3329
    -0.0028 (-0.2079%)
     
  • USD/JPY

    104.1450
    -0.1050 (-0.1007%)
     
  • BTC-USD

    17,056.54
    -110.11 (-0.64%)
     
  • CMC Crypto 200

    333.50
    -37.02 (-9.99%)
     
  • FTSE 100

    6,333.76
    -29.17 (-0.46%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that the Company will host a conference call and webcast on April 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2020 financial results.

The conference call can be accessed by dialing 1-800-479-1004 (toll-free domestic) or 1-720-543-0206 (international) and using the conference ID 6494327. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These product candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and in combination with pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
650-900-4522
LLea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com